ROCKVILLE, Md.--(BUSINESS WIRE)--Bacilligen, Inc. announced today the receipt of a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the US National Institutes of Health (NIH), to develop an influenza vaccine based on the Company’s BVS vaccine vector platform.
